Barinthus Total Current Liabilities vs Total Stockholder Equity Analysis
| BRNS Stock | 0.95 0.02 2.06% |
Barinthus Biotherapeutics financial indicator trend analysis is way more than just evaluating Barinthus Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Barinthus Biotherapeutics is a good investment. Please check the relationship between Barinthus Biotherapeutics Total Current Liabilities and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Total Current Liabilities vs Total Stockholder Equity
Total Current Liabilities vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Barinthus Biotherapeutics Total Current Liabilities account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Barinthus Biotherapeutics' Total Current Liabilities and Total Stockholder Equity is 0.95. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Barinthus Biotherapeutics plc, assuming nothing else is changed. The correlation between historical values of Barinthus Biotherapeutics' Total Current Liabilities and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Barinthus Biotherapeutics plc are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Total Current Liabilities i.e., Barinthus Biotherapeutics' Total Current Liabilities and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.95 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Total Current Liabilities
Total Current Liabilities is an item on Barinthus Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Barinthus Biotherapeutics plc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Barinthus Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Barinthus Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Tax Provision is likely to gain to about (4.1 M) in 2024. Selling General Administrative is likely to drop to about 22.5 M in 2024
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.7M | 19K | 28K | 26.6K | Depreciation And Amortization | 601.9K | 5.5M | 5.5M | 5.7M |
Barinthus Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Barinthus Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.